Mechanisms of Belatacept (Nulojix) Effect on Alloimmunity and Antiviral Response After Kidney Transplantation - (BMS Study# IM 103-309)

Trial Profile

Mechanisms of Belatacept (Nulojix) Effect on Alloimmunity and Antiviral Response After Kidney Transplantation - (BMS Study# IM 103-309)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs Belatacept (Primary) ; Calcineurin inhibitors; Mycophenolate mofetil; Prednisone
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics
  • Most Recent Events

    • 22 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.
    • 24 Oct 2016 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
    • 24 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top